|
Real-time Estimate
Cboe Europe
16:11:18 20/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 1,865.75 GBX | +0.58% |
|
+6.30% | +2.14% |
| 11:02am | Early US flu season, current strain may signal risk for younger people; doctors urge shots | RE |
| 09:36am | GSK Jemperli Gets US Approval for Advanced Rectal Cancer | MT |
| Market Cap | 74.33B 99B 88.25B 81.75B 139B 9,386B 142B 981B 386B 4,906B 371B 364B 15,683B | P/E 2026 * |
14x | P/E 2027 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 95.51B 127B 113B 105B 179B 12,060B 182B 1,260B 495B 6,303B 477B 467B 20,151B | EV / Sales 2026 * |
2.82x | EV / Sales 2027 * | 2.61x |
| Free-Float |
92.75% | Yield 2026 * |
3.74% | Yield 2027 * | 4.03% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Deutsche Boerse AG
| GS71 | Delayed | |
|
OTC Markets
| GLAXF | Delayed | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Börse Stuttgart
| GS71 | Delayed |
Last Transcript: GSK plc
| 1 day | +0.43% | ||
| 1 week | +6.39% | ||
| Current month | +1.80% | ||
| 1 month | -2.41% | ||
| 3 months | -0.90% | ||
| 6 months | -13.01% | ||
| Current year | +2.22% |
| 1 week | 1,740 |  | 2,158 |
| 1 month | 1,735.5 | | 2,158 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,592 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 31/12/2025 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 30/04/2023 |
James Ford
CMP | Compliance Officer | - | 31/07/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 05/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 31/12/2017 |
Jonathan Symonds
CHM | Chairman | 67 | 31/08/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 22/09/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 18/09/26 | Buy | Director | 768 | 0.0000% | ||
| 18/09/26 | Buy | Director | 1,734 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.49% | +6.39% | +14.17% | +27.56% | 99B | |
| +4.55% | +10.85% | +59.85% | +121.18% | 1,106B | |
| +1.95% | +4.14% | +33.65% | +69.22% | 612B | |
| +1.90% | +5.08% | +24.24% | +97.16% | 500B | |
| +2.30% | +7.81% | +37.99% | +62.30% | 367B | |
| +3.10% | +4.23% | +71.43% | +44.13% | 354B | |
| +1.26% | +5.38% | +20.72% | +48.25% | 286B | |
| +1.02% | +5.26% | -0.33% | +20.06% | 256B | |
| +2.10% | +5.31% | +43.33% | +55.93% | 230B | |
| +1.37% | +5.44% | +26.69% | +100.48% | 190B | |
| Average | +1.95% | +2.39% | +33.17% | +64.63% | 399.91B | |
| Weighted average by Cap. | +2.58% | +2.36% | +40.11% | +79.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.9B 45.16B 40.25B 37.29B 63.62B 4,281B 64.67B 447B 176B 2,238B 169B 166B 7,153B | 35.51B 47.3B 42.16B 39.05B 66.63B 4,484B 67.73B 468B 184B 2,344B 177B 174B 7,492B |
| Net income | 5.36B 7.13B 6.36B 5.89B 10.05B 676B 10.22B 70.66B 27.78B 354B 26.77B 26.21B 1,130B | 6.23B 8.29B 7.39B 6.85B 11.68B 786B 11.87B 82.12B 32.29B 411B 31.11B 30.46B 1,313B |
| Net Debt | 21.18B 28.2B 25.14B 23.29B 39.74B 2,674B 40.39B 279B 110B 1,398B 106B 104B 4,468B | 18.29B 24.37B 21.72B 20.12B 34.33B 2,310B 34.89B 241B 94.9B 1,207B 91.42B 89.51B 3,860B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/10/26 | GBX 1,862.00 | +0.38% | 1,782,253 |
| 19/10/26 | GBX 1,855.00 | -0.40% | 4,924,879 |
| 16/10/26 | GBX 1,862.50 | -0.32% | 12,806,915 |
| 15/10/26 | GBX 1,868.50 | +2.89% | 12,523,823 |
| 14/10/26 | GBX 1,816.00 | +3.59% | 7,627,221 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
